JohnFGerecitanoMD

Oncology • New York, NY

Hematologic Oncology

Assistant Professor, Medicine, Weill Cornell Medical College

Join to view full profile

Dr. Gerecitano is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Gerecitano's full profile

Already have an account?

Office
1275 York Ave
New York, NY 10021
Phone+1 646-227-3813
Is this information wrong?

Education & Training

Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2003 - 2006
University of Pennsylvania Health SystemResidency, Internal Medicine, 2000 - 2003
New York University School of MedicineClass of 2000

Certifications & Licensure

NJ State Medical License 2006 - 2025
NY State Medical License 2003 - 2018
PA State Medical License 2001 - 2003

Clinical Trials

Bortezomib in Treating Patients With Lymphoproliferative Disorders Start of enrollment: 2001 Jun 01
Completed
Phase 2
Bortezomib, Rituximab, Cyclophosphamide, and Prednisone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma Start of enrollment: 2005 Dec 13
Completed
Phase 1, Phase 2
Lenalidomide in Treating Patients With AIDS-Associated Kaposi's Sarcoma Start of enrollment: 2010 Aug 27
Completed
Phase 1, Phase 2
Safety and Efficacy Study of a BTK Inhibitor in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma Start of enrollment: 2011 May 01
Completed
Phase 2
Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors Start of enrollment: 2011 Jul 01
Completed
Phase 1, Phase 2
The First-in-human Phase I Trial of PU-H71 in Patients With Advanced Malignancies Start of enrollment: 2011 Jul 06
Completed
Phase 1
Safety and Efficacy of AEB071 and EVEROLIMUS in Patients With CD79-mutant or ABC Subtype Diffuse Large B-Cell Lymphoma Start of enrollment: 2013 Dec 05
Completed
Phase 1
Join now to see all

Publications & Presentations

PubMed

Bendamustine in combination with ofatumumab as first line treatment for elderly patients with mantle cell lymphoma: a phase II risk-adapted design.
Anita Kumar, Carla Casulo, Erel Joffe, Craig Moskowitz, John Gerecitano, Alison Moskowitz, Anas Younes, Pamela Drullinsky, Esther Drill, Morgan Choma, Clare Grieve, As...> ;Leukemia & Lymphoma. 2022 Dec 1
9 citations
Phase I/Ib Study of the Efficacy and Safety of Buparlisib and Ibrutinib Therapy in MCL, FL, and DLBCL with Serial Cell-Free DNA Monitoring.
Caitlin Stewart, Laure Michaud, Karissa Whiting, Reiko Nakajima, Chelsea Nichols, Stephanie De Frank, Paul A. Hamlin, Matthew J. Matasar, John F. Gerecitano, Pamela Dr...> ;Clinical Cancer Research. 2021 Oct 6
5 citations
Prephase rituximab/prednisone therapy and aging-related, pro-inflammatory cytokine milieu in older, vulnerable patients with newly diagnosed diffuse large B-cell lymphoma
Richard J. Lin, Colette Owens, Esther Drill, Augustine Iannotta, Mayan Oliveros, Dylan L Schick, Ariela Noy, John F. Gerecitano, Pamela Drullinsky, Philip Caron, Anita...> ;Haematologica. 2021 Jul 22
5 citations
Comparison of immunohistochemistry and gene expression profiling subtyping for diffuse large B-cell lymphoma in the phase III clinical trial of R-CHOP ± ibrutinib.
Sriram Balasubramanian, Songbai Wang, Christopher Major, Brendan P. Hodkinson, Michael Schaffer, Laurie H. Sehn, Peter Johnson, Pier Luigi Zinzani, Jodi Carey, S. Mart...> ;British Journal of Haematology. 2021 May 3
6 citations
Active surveillance of primary extranodal marginal zone lymphoma of bronchus-associated lymphoid tissue.
Erel Joffe, Yan Leyfman, Esther Drill, Sridevi Rajeeve, Andrew D. Zelenetz, M. Lia Palomba, Craig H. Moskowitz, Carol S. Portlock, Ariela Noy, Steven M. Horwitz, John ...> ;Blood Advances. 2021 Jan 26
8 citations
Noninvasive Monitoring of Mantle Cell Lymphoma by Immunoglobulin Gene Next-Generation Sequencing in a Phase 2 Study of Sequential Chemoradioimmunotherapy Followed by A...
Anita Kumar, Kurt S. Bantilan, Allison P. Jacob, A. Park, S.F. Schoninger, Craig S. Sauter, Gary A. Ulaner, Carla Casulo, Malek Faham, K.A. Kong, Ravinder K. Grewal, J...> ;Clinical Lymphoma, Myeloma & Leukemia. 2021 Jan 1
17 citations
Positron-emission tomography-based staging reduces the prognostic impact of early disease progression in patients with follicular lymphoma.
Connie Lee Batlevi, Fushen Sha, Anna Alperovich, Ai Ni, Katy Smith, Zhitao Ying, John F. Gerecitano, Paul A. Hamlin, Steve Horwitz, Erel Joffe, Anita Kumar, Matthew J....> ;European Journal of Cancer. 2020 Jan 8
34 citations
Paradigms for Precision Medicine in Epichaperome Cancer Therapy.
Nagavarakishore Pillarsetty, Komal Jhaveri, Tony Taldone, Eloisi Caldas-Lopes, Blesida Punzalan, Suhasini Joshi, Alexander Bolaender, Mohammad M. Uddin, Anna Rodina, P...> ;Cancer Cell. 2019 Nov 11
42 citations
Active surveillance for nodular lymphocyte-predominant Hodgkin lymphoma
Sven Borchmann, Erel Joffe, Craig H. Moskowitz, Andrew D. Zelenetz, Ariela Noy, Carol S. Portlock, John F. Gerecitano, Connie Lee Batlevi, Philip Caron, Pamela Drullin...> ;Blood. 2019 May 16
112 citations
Comprehensive Safety Analysis of Venetoclax Monotherapy for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia
Matthew S. Davids, Michael Hallek, William G. Wierda, Andrew W. Roberts, Stephan Stilgenbauer, Jeffrey A. Jones, John F. Gerecitano, Su Young Kim, Jalaja Potluri, Todd...> ;Clinical Cancer Research. 2018 Sep 15
19 citations
Integrated DNA/RNA targeted genomic profiling of diffuse large B-cell lymphoma using a clinical assay.
Andrew M. Intlekofer, Erel Joffe, Connie L Batlevi, Patrick Hilden, Jie He, Venkatraman E. Seshan, Andrew D. Zelenetz, M. Lia Palomba, Craig H. Moskowitz, Carol S. Por...> ;Blood Cancer Journal. 2018 Jun 12
548 citations
Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia
John F. Seymour, Thomas J. Kipps, Barbara Eichhorst, Peter Hillmen, James D’Rozario, Sarit Assouline, Carolyn Owen, John F. Gerecitano, Tadeusz Robak, Javier de la Ser...> ;The New England Journal of Medicine. 2018 Mar 21
46 citations
A phase 1 study of ibrutinib in combination with R-ICE in patients with relapsed or primary refractory DLBCL
Craig S. Sauter, Matthew J. Matasar, Heiko Schöder, Sean M. Devlin, Pamela Drullinsky, John F. Gerecitano, Anita Kumar, Ariela Noy, Maria Lia Palomba, Carol S. Portloc...> ;Blood. 2018 Apr 19
66 citations
In Vivo PET Assay of Tumor Glutamine Flux and Metabolism: In-Human Trial of 18F-(2S,4R )-4-Fluoroglutamine
Mark Dunphy, James J. Harding, Sriram Venneti, Hanwen Zhang, Eva Burnazi, Jacqueline Bromberg, Antonio Omuro, James J. Hsieh, Ingo K. Mellinghoff, Kevin Staton, Christ...> ;Radiology. 2018 Jan 31
88 citations
Prognostic significance of baseline metabolic tumor volume in relapsed and refractory Hodgkin lymphoma.
Alison J. Moskowitz, Heiko Schöder, Somali Gavane, Katie L. Thoren, Martin Fleisher, Joachim Yahalom, Susan J. McCall, Briana R. Cadzin, Stephanie Y. Fox, John F. Gere...> ;Blood. 2017 Nov 16
38 citations
Pan-phosphatidylinositol 3-kinase inhibition with buparlisib in patients with relapsed or refractory non-Hodgkin lymphoma
Anas Younes, Gilles Salles, Giovanni Martinelli, Robert G. Bociek, Dolores Caballero Barrigon, Eva González Barca, Mehmet Turgut, John F. Gerecitano, O Kong, Chaitali ...> ;Haematologica. 2017 Dec 1
52 citations
Brentuximab vedotin and AVD followed by involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma
Anita Kumar, Carla Casulo, Joachim Yahalom, Heiko Schöder, Paul M. Barr, Philip Caron, April Chiu, Louis S. Constine, Pamela Drullinsky, Jonathan W. Friedberg, John F....> ;Blood. 2016 Sep 15
59 citations
INHIBITION OF THE NUCLEAR EXPORT RECEPTOR XPO1 AS A THERAPEUTIC TARGET FOR PLATINUM RESISTANT OVARIAN CANCER
Ying Chen, Sandra Catalina Camacho, Thomas R. Silvers, Albiruni Ryan Abdul Razak, Nashat Y. Gabrail, John F. Gerecitano, Eva Kalir, Elena Pereira, Brad R. Evans, Susan...> ;Clinical Cancer Research. 2017 Mar 15
10 citations
A phase 1b dose expansion study of the pan-class I PI3K inhibitor buparlisib (BKM120) plus carboplatin and paclitaxel in PTEN deficient tumors and with dose intensifie...
Lillian M. Smyth, Kelsey R. Monson, Komal Jhaveri, Alexander Drilon, Bob T. Li, Wassim Abida, Gopa Iyer, John F. Gerecitano, Mrinal M. Gounder, James J. Harding, Marti...> ;Investigational New Drugs. 2017 Mar 9
492 citations
Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
Matthew S. Davids, Andrew W. Roberts, John F. Seymour, John M. Pagel, Brad S. Kahl, William G. Wierda, Soham D. Puvvada, Thomas J. Kipps, Mary Ann Anderson, Ahmed Sale...> ;Journal of Clinical Oncology. 2017 Jan 17
212 citations
A Phase I Study of the Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib (LEE011) in Patients With Advanced Solid Tumors and Lymphomas
Jeffrey R. Infante, P. A. Cassier, John F. Gerecitano, Petronella O. Witteveen, Rashmi Chugh, Vincent Ribrag, Abhijit Chakraborty, Alessandro Matano, Adam S. Crystal, ...> ;Clinical Cancer Research. 2016 Dec 1
168 citations
First-in-Class, First-in-Human Phase I Study of Selinexor, a Selective Inhibitor of Nuclear Export, in Patients With Advanced Solid Tumors
Albiruni Ryan Abdul Razak, Morten Mau-Soerensen, Nashat Y. Gabrail, John F. Gerecitano, Anthony F. Shields, Thaddeus J. Unger, Jean Richard Saint-Martin, Robert W. Car...> ;Journal of Clinical Oncology. 2016 Oct 31
177 citations
The epichaperome is an integrated chaperome network that facilitates tumour survival
Anna Rodina, Tai Wang, Pengrong Yan, Erica DaGama Gomes, Mark Dunphy, Nagavarakishore Pillarsetty, John Koren, John F. Gerecitano, Tony Taldone, Hongliang Zong, Eloisi...> ;Nature. 2016 Oct 20
119 citations
Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma o...
Anas Younes, Jesus G. Berdeja, Manish R. Patel, Ian W. Flinn, John F. Gerecitano, Sattva S. Neelapu, Kevin R. Kelly, Amanda R Copeland, Amy Akins, Myles Clancy, Lucy G...> ;The Lancet. Oncology. 2016 May 1
1278 citations
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
Andrew W. Roberts, Matthew S. Davids, John M. Pagel, Brad S. Kahl, Soham D. Puvvada, John F. Gerecitano, Thomas J. Kipps, Mary Ann Anderson, Jennifer R. Brown, Lori A....> ;The New England Journal of Medicine. 2016 Jan 27
Join now to see all

Press Mentions

EZH2 Inhibitor Tested as Epigentic Option in NHL TypesOctober 26th, 2017
Two Late-Stage Trials Test Novel PI3K Inhibitor in Non-Hodgkin LymphomaJune 16th, 2017
$LBA-2 Venetoclax plus Rituximab Is Superior to Bendamustine plus Rituximab in Patients with Relapsed/ Refractory Chronic Lymphocytic Leukemia - Results from Pre-Planned Interim Analysis of the Randomized Phase 3 Murano Study$
LBA-2 Venetoclax plus Rituximab Is Superior to Bendamustine plus Rituximab in Patients with Relapsed/ Refractory Chronic Lymphocytic Leukemia - Results from Pre-Planned Interim Analysis of the Randomized Phase 3 Murano StudyDecember 2nd, 2017